CN3924657
Active
Amendment A1
Imported Plasma and Recombinant Products
National Blood Authority contracted TAKEDA PHARMACEUTICALS AUSTRALIA PTY. LTD. for AU$30,209,374 to supply imported plasma and recombinant products from September 2022 to September 2027 under limited tender procurement. The contract has one amendment.
$30.2M
Contract Value
Contract Details
- Contract ID
- CN3924657
- Status
- active
- Financial Year
- FY27
- Category
- Drugs and Pharmaceutical(UNSPSC: 51000000)
Key Dates
- Publish Date
- 16 July 2026
- Signed Date
- 2 Nov 2022
- Start Date
- 30 Sept 2022
- End Date
- 29 Sept 2027
- Duration
- 5 years, 1 month
Procurement Information
- Procurement Method
- Limited tender
- Exemption Code
- BP
- Exemption Reason
- App A: 11. Blood plasma products or plasma fractionation services.
Contract History
This contract has been amended 1 time. Currently showing amendment A1.
Original Contract
Published 2 Nov 2022 · 30 Sept 2022 to 29 Sept 2027
$11.8M
Amendment A1
Current
Published 16 July 2026 · 30 Sept 2022 to 29 Sept 2027
$30.2M
+$18.4M
Supplier
TAKEDA PHARMACEUTICALS AUSTRALIA PTY. LTD.
- ABN
- 71 095 610 870
- Entity Type
- Australian Private Company
- Location
- NSW
Agency
More from TAKEDA PHARMACEUTICALS AUSTRALIA PTY. LTD.
National Supply arrangement for imported immunoglobulin products
$434.1MNational Blood Authority
Supply of Advate and Adynovate
Imported Plasma and Recombinant Products
$109.5MNational Blood Authority
Procurement of Imported Plasma and Recombinant Products (IPRP) – Adynovate
$22.3MNational Blood Authority